Besivance Ophthalmic Solution: Effective Bacterial Conjunctivitis Treatment
| Product dosage: 5 ml | |||
|---|---|---|---|
| Package (num) | Per flacon | Price | Buy |
| 2 | $22.65 | $45.30 (0%) | 🛒 Add to cart |
| 3 | $19.80 | $67.94 $59.39 (13%) | 🛒 Add to cart |
| 4 | $19.38 | $90.59 $77.51 (14%) | 🛒 Add to cart |
| 5 | $17.72
Best per flacon | $113.24 $88.58 (22%) | 🛒 Add to cart |
Synonyms | |||
Besivance (besifloxacin ophthalmic suspension) 0.6% is a prescription topical ophthalmic solution indicated for the treatment of bacterial conjunctivitis. As a member of the fluoroquinolone class of antibiotics, it is specifically formulated to target and eradicate a broad spectrum of ocular pathogens. Its advanced suspension technology ensures optimal drug delivery and prolonged contact time with the ocular surface. This product is designed for use in patients one year of age and older, providing a potent therapeutic option for eye care professionals.
Features
- Active Ingredient: Besifloxacin hydrochloride 0.6% (equivalent to 6 mg/g besifloxacin)
- Drug Class: Fluoroquinolone antibiotic
- Dosage Form: Sterile, preserved, white to off-white topical ophthalmic suspension
- Presentation: Supplied in a 5 mL white, low-density polyethylene (LDPE) bottle with a controlled dropper tip and a white polypropylene cap
- Preservative: Benzalkonium chloride 0.01%
- Inactive Ingredients: Durasorb, sodium chloride, mannitol, edetate disodium, sodium hydroxide, and/or hydrochloric acid (to adjust pH), and purified water
Benefits
- Provides potent bactericidal activity against a wide range of gram-positive and gram-negative ocular pathogens, including key resistant strains.
- Formulated with Durasorb technology to enhance viscosity and prolong ocular surface residence time, improving bioavailability.
- Demonstrated high clinical efficacy rates in eradicating the causative bacteria and resolving the signs and symptoms of bacterial conjunctivitis.
- Low systemic absorption minimizes the risk of systemic side effects, focusing treatment on the site of infection.
- Convenient twice-daily dosing regimen supports patient adherence to the treatment protocol.
- Indicated for use in a pediatric population as young as one year of age, expanding treatment options for younger patients.
Common use
Besivance Ophthalmic Solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans, Corynebacterium pseudodiphtheriticum, Corynebacterium striatum, Haemophilus influenzae, Moraxella catarrhalis, Propionibacterium acnes, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus warneri, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius. It is crucial to note that this medication is not effective against viral or fungal conjunctivitis. Diagnosis should be confirmed by a healthcare professional to ensure appropriate antimicrobial therapy.
Dosage and direction
- The recommended dosage for patients one year of age and older is one drop instilled into the affected eye(s) twice daily, approximately 8 to 12 hours apart, for 7 days.
- Patients should be instructed to wash their hands thoroughly before administration.
- To avoid contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip.
- If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart. Ointments should be administered last.
- Instructions for use: Shake the bottle well before each use. Tilt the head back, pull down the lower eyelid to create a pouch, instill one drop into the pouch, close the eye gently, and apply light pressure to the tear duct (nasolacrimal duct) for 1 to 2 minutes. This helps to maximize ocular absorption and minimize systemic absorption.
Precautions
- Systemic Effects: As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy.
- Contact Lens Wear: Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis. The preservative in Besivance, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses should not be inserted during the course of therapy.
- Topical Use Only: Besivance is intended for topical ophthalmic use only and should not be injected subconjunctivally, introduced into the anterior chamber of the eye, or used for systemic administration.
- Sensitization: There is a potential for sensitization and subsequent allergic reactions to besifloxacin upon re-exposure. Cross-sensitivity to other quinolones may occur.
- Patient Advice: Patients should be instructed to avoid allowing the dropper tip to contact any surface to prevent contamination of the solution. The bottle should be tightly closed when not in use.
Contraindications
Besivance Ophthalmic Solution is contraindicated in patients with a history of hypersensitivity to besifloxacin, to other quinolones, or to any of the components in this medication.
Possible side effect
The most frequently reported ocular adverse reactions in patients treated with Besivance occurring in approximately 1-3% of patients were:
- Blurred vision (instillation site disturbance)
- Eye pain
- Eye irritation
- Eye pruritus (itching) Other ocular adverse reactions reported in less than 1% of patients included conjunctival redness, eye discharge, dry eye, eye redness, and headache. As with all antibacterial preparations, prolonged use may result in fungal overgrowth.
Drug interaction
Although systemic absorption is low following topical ocular administration, the potential for interaction with systemically administered quinolones cannot be ruled out. Formal drug interaction studies have not been conducted with Besivance. The concomitant use of other topical ophthalmic medications may increase the risk of local adverse reactions. Administer other eye drops at least 5 minutes before Besivance.
Missed dose
If a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. The patient should not instill a double dose to make up for the missed one.
Overdose
Topical ocular overdose of Besivance is unlikely to produce clinical manifestations. It may be flushed from the eye(s) with warm tap water. If accidentally ingested, standard supportive measures should be employed. Due to the low systemic exposure, systemic adverse events are not anticipated.
Storage
- Store at 2°C to 25°C (36°F to 77°F).
- Protect from freezing.
- Keep the bottle tightly closed when not in use.
- Discard the bottle within one (1) month of opening to prevent contamination and potential loss of potency.
Disclaimer
This information is intended for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The complete official prescribing information should be consulted before initiating treatment.
Reviews
“Besivance has become a reliable first-line option in my practice for bacterial conjunctivitis. Its broad-spectrum coverage, particularly against methicillin-resistant Staphylococcus species, is a significant advantage. The twice-daily dosing is well-tolerated by patients and promotes excellent adherence to the full treatment course.” – Ophthalmologist, 12 years experience.
“In clinical trials and my own use, Besivance demonstrates rapid and effective resolution of purulent discharge and conjunctival injection. The formulation stays on the eye well, which I attribute to its suspension vehicle. It’s a potent tool against common and resistant pathogens.” – Optometrist, specializing in ocular disease.
“I’ve prescribed this for pediatric patients (over 1 year) and adults. The efficacy is consistently high, and the safety profile is excellent. Parents appreciate the clear dosing instructions and the relatively short treatment duration.” – Pediatric Ophthalmologist.